Table 2.
Comparisons of lymphocyte subsets between the ARDS and non-ARDS patients.
| Variables | Normal ranges /μL | Total (n = 227) | Non-ARDS (n = 100) | ARDS (n = 127) | P |
|---|---|---|---|---|---|
| Total lymphocytes /μL | 800–4,000 | 887.0 ± 520.3 | 1040.3 ± 515.1 | 766.2 ± 493.7 | <0.001 |
| T cells (CD3+) /μL | 940–2,140 | 485.0 (267.5, 756.0) | 677.0 (340.2, 898.5) | 363.0 (239.5, 617.5) | <0.001 |
| T cells (CD3 + CD8+) /μL | 380–790 | 160.0 (94.0, 270.0) | 211.0 (107.0, 294.8) | 127.0 (75.5, 251.0) | <0.001 |
| T cells (CD3 + CD4+) /μL | 550–1,200 | 235.0 (143.0, 426.0) | 378.0 (204.8, 533.8) | 193.0 (121.5, 332.0) | <0.001 |
| NK cells (CD16 + CD56+) /μL | 155–550 | 131.0 (71.0, 229.0) | 153.5 (104.2, 250.5) | 107.0 (54.0, 213.0) | <0.001 |
| B cells (CD19+) /μL | 160–350 | 97.0 (55.5, 166.5) | 108.0 (61.8, 193.5) | 85.0 (47.0, 150.5) | 0.052 |
| CD4+/CD8 + ratio | 0.9–2.0 | 1.6 (1.0, 2.4) | 1.6 (1.2, 2.2) | 1.5 (0.9, 2.4) | 0.597 |
NK cell, natural killer cells. The P-values denote the statistical significance of comparisons between the non-ARDS and ARDS groups.